Health Trials

Axatilimab + CAR-T for High-Risk Lymphoma

ConditionsDiffuse Large B Cell Lymphoma (DLBCL)Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma (HGBCL)High-Grade B-Cell Lymphoma, NosPMBCLFollicular Grade 3 Lymphoma
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age8+
SponsorNorthside Hospital, Inc.

About this trial

Axatilimab + CAR-T in High-Risk Lymphoma

Eligibility criteria

Qualifiers

Age ≥ 18 years

Histologically confirmed large B-cell lymphoma

Presence of one or more high-risk features

Eligible to receive CAR-T according to the FDA label

Disqualifiers

KPS <60

Second malignancy with a high metastatic potential within 3 years

Active CNS involvement. Treated CNS disease is allowed

Active HBV or HCV infection.

Trial design

Treatments tested in this trial

  • Axatilimab

Treatment groups

29 Participants
are divided into 1 treatment group

Sponsors and collaborators

Northside Hospital, Inc.

Lead sponsor

Source ClinicalTrials.gov